CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & DevelopmentGlobeNewswire (press release)ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused o… Continue reading
CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & DevelopmentGlobeNewswire (press release)ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused o… Continue reading
Kite first to submit CAR-T therapy in EuropePharmaTimesKite Pharma has submitted the first CAR-T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin … Continue reading
FierceBiotech |
Chiesi dumps uniQure’s hemophilia B gene therapy
FierceBiotech Chiesi has cut its ties to uniQure’s hemophilia B gene therapy. The split gives uniQure full rights to AMT-060 but leaves it without a partner to cofund R&D as it closes in on the start of a pivotal trial. Italian drugmaker Chiesi picked up the rights … |
Reuters |
AstraZeneca a tricky takeover target after big cancer drug blow
Reuters Two other new cancer medicines, Tagrisso and Lynparza, are doing well, while its troubled immunotherapy drug Imfinzi should still be a significant seller for non-metastatic lung cancer, despite the big hit to the firm’s chances in advanced disease. BMS takes AstraZeneca to court over cancer treatmentLife Sciences Intellectual Property Review (subscription) |
|
Isogenica Announces New Licence Agreement with Takeda
Business Wire (press release) Isogenica is a synthetic biology company focusing on the design and build of diverse antibody libraries for use in biopharmaceuticals. Partners can access an advanced camelid single-domain antibody library (llamdA™) and state-of-the-art, fully … |